Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases

Autor: Kevin K. Brown, Yoshikazu Inoue, Kevin R. Flaherty, Fernando J. Martinez, Vincent Cottin, Francesco Bonella, Stefania Cerri, Sonye K. Danoff, Stephane Jouneau, Rainer‐Georg Goeldner, Martin Schmidt, Susanne Stowasser, Rozsa Schlenker‐Herceg, Athol U. Wells
Přispěvatelé: National Jewish Health (NJH), University of Michigan [Ann Arbor], University of Michigan System, Weill Cornell Medicine [New York], Centre de Référence des Maladies Pulmonaires Rares [Hôpital Louis Pradel - HCL], Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Ruhrlandklinik University Hospital, Azienda Ospedaleria Universitaria di Modena, Johns Hopkins University School of Medicine [Baltimore], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), École des Hautes Études en Santé Publique [EHESP] (EHESP), Boehringer Ingelheim Pharma GmbH & Co. KG, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, Boehringer Ingelheim International GmbHBoehringer Ingelheim, Chard-Hutchinson, Xavier, Weill Cornell Medicine [Cornell University], Cornell University [New York]
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Respirology
Respirology, 2022, 27 (4), pp.294-300. ⟨10.1111/resp.14231⟩
ISSN: 1323-7799
1440-1843
DOI: 10.1111/resp.14231⟩
Popis: International audience; Background and objective Demographic and clinical variables, measured at baseline or over time, have been associated with mortality in subjects with progressive fibrosing interstitial lung diseases (ILDs). We used data from the INPULSIS trials in subjects with idiopathic pulmonary fibrosis (IPF) and the INBUILD trial in subjects with other progressive fibrosing ILDs to assess relationships between demographic/clinical variables and mortality. Methods The relationships between baseline variables and time-varying covariates and time to death over 52 weeks were analysed using pooled data from the INPULSIS trials and, separately, the INBUILD trial using a Cox proportional hazards model. Results Over 52 weeks, 68/1061 (6.4%) and 33/663 (5.0%) subjects died in the INPULSIS and INBUILD trials, respectively. In the INPULSIS trials, a relative decline in forced vital capacity (FVC) >10% predicted within 12 months (hazard ratio [HR] 3.77) and age (HR 1.03 per 1-year increase) were associated with increased risk of mortality, while baseline FVC % predicted (HR 0.97 per 1-unit increase) and diffusing capacity of the lungs for carbon monoxide (DLCO) % predicted (HR 0.77 per 1-unit increase) were associated with lower risk. In the INBUILD trial, a relative decline in FVC >10% predicted within 12 months (HR 2.60) and a usual interstitial pneumonia-like fibrotic pattern on HRCT (HR 2.98) were associated with increased risk of mortality, while baseline DLCO % predicted (HR 0.95 per 1-unit increase) was associated with lower risk. Conclusion These data support similarity in the course of lung injury between IPF and other progressive fibrosing ILDs and the value of FVC decline as a predictor of mortality.
Databáze: OpenAIRE
Externí odkaz: